ObsEva SA

OTCPK:OBSE.F Aktierapport

Börsvärde: US$11.7k

ObsEva Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

Det finns inte tillräckligt med data om ObsEva s resultat under de senaste åren.

Viktig information

n/a

Tillväxttakt i vinsten

n/a

Tillväxttakt för EPS

Biotechs Tillväxt i branschen17.04%
Intäkternas tillväxttaktn/a
Avkastning på eget kapitaln/a
Nettomarginaln/a
Senaste uppdateringen av resultatet30 Jun 2023

Senaste uppdateringar av tidigare prestationer

Recent updates

Seeking Alpha • Aug 22

ObsEva stock dips on Nasdaq non-compliance notice

ObsEva SA (NASDAQ:OBSV) received a notice from Nasdaq for failing to comply with the rule of maintaining a minimum of $10M in stockholders' equity for continued listing on the exchange. The company had disclosed in a SEC filing that as of June 30, it had shareholders' equity of ~$2.10M. ObsEva has until Aug. 29 to submit a plan to regain compliance after Nasdaq decided to provide a shortened response time to the company. The company said it intends to submit plan by the date. On July 27, ObsEva stock fell ~78% on plans to restructure following setback for uterine fibroids drug. Earlier in August, the company said it was retiring $31M in debt and had announced $11M debt refinancing. OBSV -4.13% to $0.23 premarket Aug. 22
Seeking Alpha • Aug 01

ObsEva to retire $31M in debt and announces $11M debt refinancing

ObsEva (NASDAQ:OBSV) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to the outstanding debt held by JGB. Under agreement terms, ObsEva and JGB agreed to apply the $31M cash earlier held as collateral in a control account against the outstanding convertible notes on a pro rata basis, with JGB waiving a 25% prepayment penalty on the early debt retirement. JGB has agreed to forbear for a period of up to three months from enforcing any rights or remedies under the notes. In exchange, $1.5M was added to the outstanding principal balance under the notes, leading to ~$11M of convertible notes outstanding, and the conversion price of the notes was adjusted to a conversion price of $0.26/share. Shares trading 1.6% higher premarket.
Seeking Alpha • Jul 05

ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for the treatment of women with uterine fibroids set for September 13, 2022. Trial results from the phase 3 EDELWEISS 3 study and long-term extension study for endometriosis are expected 2nd half of 2022; Post-treatment follow-up results from extension study expected early 2023. ObsEva SA (OBSV) is a great long-term biotech to own. The reason why I state that is because despite having received regulatory approval in two territories for linzagolix (marketed as Yselty) for the treatment of women with uterine fibroids, the stock still trades at a very low share price. It received approval of this drug for the treatment of this patient population for the European Union and for the United Kingdom. I believe there is long-term potential just based on these approvals. However, there is an ability to further expand the reach of Yselty to the United States. That's because there is a PDUFA date set for September 13, 2022, and that is when the FDA will decide if this drug should be approved for the very same patient population for use in the United States. I believe that the FDA approval may carry more weight compared to the other two regulatory approvals. Not only that, but the biotech won't have to attempt to sell the drug on its own. Instead, it has already been able to establish two partners for specific territories. It established a partnership for Theramex to sell the drug outside of the U.S., Canada, and Asia. The other partnership that was established was with Syneos Health to sell the drug within the United States upon regulatory approval. It is developing Yselty (linzagolix) for another large market indication which is endometriosis as well. With a few regulatory approvals for Yselty, plus another possible one on the way in Q3 of 2022, these are the reasons why I believe that ObsEva is a great long-term biotech to look into. Two Regulatory Approvals With A Third One Being Possible As I noted directly above, ObsEva received regulatory approvals of Yselty for the treatment of women with uterine fibroids in two territories. Uterine fibroids are benign tumors that end up forming in the uterus (womb) of a woman. When I state the term "benign," that means non-cancerous. The thing is that a majority of the time there are no symptoms. However, in certain cases, they can cause severe pain for the patient. There are several symptoms that uterine fibroids can cause, which are: Heavy Menstrual bleeding Prolonged periods Pelvic pain Cramping Urge to urinate One immediate item to point out is that Yselty was explored in uterine fibroid patients with heavy menstrual bleeding. Thus, heavy menstrual bleeding ((HMB)) is one of the symptoms involved with this disease. Some ways to treat this disease are surgeries and medications. Surgeries may involve attempting to go in and remove the uterine fibroids if successful. The other option involves medications. There are two types of medications: SERMs (Selective estrogen receptor modulators) - work by changing estrogen levels in the body and holds the ability to shrink fibroids without causing menopause symptoms GnRH agonist - GnRH is a type of hormone that a person's body makes naturally. These agonist drugs act as a counter to the production of the GnRH hormone. Thus, in turn it is able to shrink fibroids and sometimes can even reduce anemia as well There are many other additional types of surgeries as well, like cutting off the blood supply to kill the fibroid off. The thing is that the uterine fibroids market is a large one. Well, it only treats women and it is just benign fibroids that are being formed in the uterus. Yes, but believe it or not it is indeed a major problem. Just in the United States alone, it is expected that the uterine fibroids treatment market is estimated to be worth $298.5 million by the end of 2027. One of the first regulatory approvals was achieved back on June 22, 2022, from the European Commission ((EC)). This approval was followed by a positive opinion from the Committee Medicinal Products for Human Use of the European Medicines Agency back in April of 2022. Then, the biotech was able to receive UK Medicines and Healthcare Products Regulatory Agency ((MHRA)) approval of Yselty for this very same patient population. The reason why Yselty was approved was because of positive results from the two phase 3 PRIMROSE studies that were done. It was noted from 24 weeks that there were huge response rates. The breakdown of such response rates is as follows: A responder rate of 84.5% in women who received 200 mg linzagolix with hormonal add back therapy ((ABT)) A responder rate of 56.5% in women who received 100 mg of linzagolix without ABT These two response rates, plus safety profile of the drug, is what allowed for these regulatory approvals. However, where I believe ObsEva may have a competitive advantage is that Yselty is the first drug approved for this specific patient population that gives women the option to be treated without the need for hormone therapy. The need for a drug like Yselty now is to help a woman either delay or avoid the need for surgery altogether. There is potential to expand regulatory approval of Yselty to the United States with the upcoming FDA decision in the 2nd half of 2022. A Prescription Drug User Fee Act ((PDUFA)) date has been established with an action date of September 13, 2022. Agreement has been made in partnership with Theramex to sell Yselty outside of the U.S., Canada and Asia. Another agreement had been made with Syneos Health to sell the drug in the United States upon regulatory approval. Financials According to the 6-K SEC Filing, ObsEva had cash and cash equivalents of $57.6 million as of March 31, 2022. It has been able to raise cash through several different methods over the years. It raised about $5.7 million of net cash in Q1 of 2022 using its at-the-market offering program. Then, made $8.3 million in proceeds from its securities purchase agreement with JGB Management. Speaking of which, this JGB Securities Purchase Agreement is structured to provide about $135 million in borrowing capacity in nine tranches. The first and second tranche were achieved, October 2021 and then January 2022 respectively.

Fördelning av intäkter och kostnader

Hur ObsEva tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

OTCPK:OBSE.F Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
30 Jun 2320815-11
31 Mar 2320-2120-5
31 Dec 2220-30250
30 Sep 224-772525
30 Jun 2222-5832-17
31 Mar 220-502543
31 Dec 2122-53250
30 Sep 210-571856
30 Jun 210-821465
31 Mar 210-811366
31 Dec 200-831268
30 Sep 200-851270
30 Jun 200-881472
31 Mar 200-1051885
31 Dec 190-1091988
30 Sep 190-1082086
30 Jun 190-991980
31 Mar 190-831667
31 Dec 180-771463
30 Sep 180-741361
30 Jun 180-721359
31 Mar 180-711358
31 Dec 170-671355
30 Sep 170-611349
30 Jun 170-521241
31 Mar 170-41933
31 Dec 160-30624
30 Sep 160-26520
30 Jun 160-21318
31 Mar 160-20316
31 Dec 150-20317

Kvalitetsintäkter: Otillräcklig data för att avgöra om OBSE.F har inkomster av hög kvalitet.

Växande vinstmarginal: Otillräcklig data för att avgöra om OBSE.F s vinstmarginaler har förbättrats under det senaste året.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: Otillräcklig data för att avgöra om OBSE.F s resultattillväxt på årsbasis var positiv under de senaste 5 åren.

Accelererande tillväxt: Otillräcklig data för att jämföra OBSE.F s intäkter under det senaste året med dess 5-åriga genomsnitt.

Resultat vs industri: Otillräcklig data för att avgöra om OBSE.F s inkomsttillväxt under det senaste året översteg branschgenomsnittet för Biotechs.

Avkastning på eget kapital

Hög ROE: OBSE.F har en negativ avkastning på eget kapital ( 0% ), eftersom det för närvarande är olönsamt.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/22 19:17
Aktiekurs vid dagens slut2026/05/22 00:00
Intäkter2023/06/30
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

ObsEva SA bevakas av 9 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Nathan WeinsteinAegis Capital Corporation
Mayur SomaiyaBMO Capital Markets Equity Research
Edward NashCanaccord Genuity